参考文献/References:
[1] Smith JGNewton-Cheh C,Almgren P,et al. Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation[J]. J Am Coll Cardiol,2010,56(21):1712-1719.
[2] Inohara T,Kim S,Pieper K,et al. B-type natriuretic peptide,disease progression and clinical outcomes in atrial fibrillation[J]. Heart,2018,pii: heartjnl-2018-313642.
[3] 黄从新,张澍,黄德嘉,等. 心房颤动:目前的认识和治疗的建议-2018[J]. 中国心脏起搏与心电生理杂志,2018,32(4):6-59.
[4] Alonso A,Lopez FL,Matsushita K,et al. Chronic kidney disease is associated with the incidence of atrial fibrillation:the Atherosclerosis Risk in Communities(ARIC) study[J]. Circulation,2011,123(25):2946-2953.
[5] Kodama S,Saito K,Tanaka S,et al. Alcohol consumption and risk of atrial fibrillation:a meta-analysis[J]. J Am Coll Cardiol,2011,57(4):427-436.
[6] Moe GK,Rheinboldt WC,Abildskov JA. A computer model of atrial fibrillation[J]. Am Heart J,1964,67(2):200-220.
[7] Nattel S,Harada M. Atrial remodeling and atrial fibrillation:recent advances and translational perspectives[J]. J Am Coll Cardiol,2014,63(22):2335-2345.
[8] Cheniti G,Vlachos K,Pambrun T,et al. Atrial fibrillation mechanisms and implications for catheter ablation[J]. Front Physiol,2018,9:1458.
[9] Narayan SM,Krummen DE,Rappel WJ. Clinical mapping approach to diagnose electrical rotors and focal impulse sources for human atrial fibrillation[J]. J Cardiovasc Electrophysiol,2012,23(5):447-454.
[10] Narayan SM,Baykaner T,Clopton P,et al. Ablation of rotor and focal sources reduces late recurrence of atrial fibrillation compared with trigger ablation alone:extended follow-up of the CONFIRM trial (Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation)[J]. J Am Coll Cardiol,2014,63(17):1761-1768.
[11] Magalh?es LP, Figueiredo MJO, Cintra FD,et al. Executive summary of the II Brazilian guidelines for atrial fibrillation[J]. Arq Bras Cardiol,2016,107(6):501-508.
[12] January CT,Wann LS,Alpert JS,et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:executive summary:a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society[J]. Circulation,2014,130(23):2071-2104.
[13] Kirchhof P,Benussi S,Kotecha D,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J]. Eur Heart J,2016,37(38):2893-2962.
[14] Andrade JG,Verma A,Mitchell LB,et al. 2018 focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation[J]. Can J Cardiol,2018,34(11):1371-1392.
[15] Joung B,Lee JM,Lee KH,et al. 2018 Korean guideline of atrial fibrillation management[J]. Korean Circ J,2018,48(12):1033-1080.
[16] Chiang CE,Okumura K,Zhang S,et al. 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation[J]. J Arrhythm,2017,33(4):345-367.
[17] Prystowsky EN,Padanilam BJ,Fogel RI. Treatment of atrial fibrillation[J]. JAMA,2015,314(3):278-288.
[18] Schnabel RB,Larson MG,Yamamoto JF,et al. Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community[J]. Circulation,2010,121(2):200-207.
[19] Sinner MF,Stepas KA,Moser CB,et al. B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk:the CHARGE-AF Consortium of community-based cohort studies[J]. Europace,2014,16(10):1426-1433.
[20] Shaikh AY,Esa N,Martin-Doyle W,et al. Addition of B-type natriuretic peptide to existing clinical risk scores enhances identification of patients at risk for atrial fibrillation recurrence after pulmonary vein isolation[J]. Crit Pathw Cardiol,2015,14(4):157-165.
[21] Tuinenburg AE,Brundel BJ,van Gelder IC,et al. Gene expression of the natriuretic peptide system in atrial tissue of patients with paroxysmal and persistent atrial fibrillation[J]. J Cardiovasc Electrophysiol,1999,10(6):827-835.
[22] Silvet H,Young-Xu Y,Walleigh D,et al. Brain natriuretic peptide is elevated in outpatients with atrial fibrillation[J]. Am J Cardiol,2003,92(9):1124-1127.
[23] Xu X,Tang Y. Relationship between brain natriuretic peptide and recurrence of atrial fibrillation after successful electrical cardioversion:an updated meta-analysis[J]. Braz J Cardiovasc Surg,2017,32(6):530-535.
[24] Engelmann MD,Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation[J]. Eur Heart J,2005,26(20):2083-2092.
[25] Aviles RJ,Martin DO,Apperson-Hansen C,et al. Inflammation as a risk factor for atrial fibrillation[J]. Circulation,2003,108(24):3006-3010.
[26] Takase H,Dohi Y,Sonoda H,et al. Prediction of atrial fibrillation by B-type natriuretic peptide[J]. J Atr Fibrillation,2013,5(6):674.
[27] Maruyama K,Uchiyama S,Shiga T,et al. Brain natriuretic peptide is a powerful predictor of outcome in stroke patients with atrial fibrillation[J]. Cerebrovasc Dis Extra,2017,7(1):35-43.
[28] Cai GL,Chen J,Hu CB,et al. Value of plasma brain natriuretic peptide levels for predicting postoperative atrial fibrillation:a systemic review and meta-analysis[J]. World J Surg,2014,38(1):51-59.
[29] Hijazi Z,Oldgren J,Andersson U,et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation:a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy[J]. Circulation,2012,125(13):1605-1616.
[30] 解忠慧. 2016年欧洲心脏学会心房颤动患者管理指南解读 心血管病学进展2018,39(2):160-164.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展通讯作者：任澎，E-mail：renpengcvd@126.com.,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(6):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展通讯作者：任澎，E-mail：renpengcvd@126.com.,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(6):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展通讯作者：任澎，E-mail：renpengcvd@126.com.,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(6):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展通讯作者：任澎，E-mail：renpengcvd@126.com.,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(6):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展通讯作者：任澎，E-mail：renpengcvd@126.com.,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(6):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展通讯作者：任澎，E-mail：renpengcvd@126.com.,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(6):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展通讯作者：任澎，E-mail：renpengcvd@126.com.,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(6):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展通讯作者：任澎，E-mail：renpengcvd@126.com.,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(6):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展通讯作者：任澎，E-mail：renpengcvd@126.com.,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(6):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展通讯作者：任澎，E-mail：renpengcvd@126.com.,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(6):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]